Guided Therapy Systems Keeps Options Open On Tissue Regen Device

13 Jun 2016

Guided Therapy Systems CEO Michael Slayton, PhD, has a history of breaking innovative medical technology, with a primary focus on diagnostic and therapeutic ultrasound applications. He tells In Vivo about the 22-year engineering journey that has led him and the company he founded to the cusp of market launch of a non-invasive tissue regeneration device for musculoskeletal injuries.

Scalpel or sound wave to treat musculoskeletal and sporting injuries? Mesa, AZ, medical device innovator Guided Therapy Systems LLC (GTS) claims it has developed a revolutionary method of treating conditions like plantar fasciitis, epicondylitis and tendon injuries that is superior to laser, radiowave or other energy delivery devices.

Revolutionary, because the product, Actisound, introduces intense therapeutic ultrasound (ITU) guided by ultrasound imaging in a device that offers a...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on In Vivo for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Podcast: “They Are Able To Keep Their Body”: Medipost On Its Stem Cell Therapy Vision

17 Jul 2025

• By Anabel Costa-Ferreira

In Vivo spoke with Edward Ahn, CEO of Medipost, a Korean company that has developed stem cell therapies from cord blood, on how they are working across regulatory markets to provide a novel treatment for degenerative diseases.

Rising Leaders 2025: Abbas Kazimi’s Vision For Nimbus Therapeutics

16 Jul 2025

• By David Wild

Rising Leader Abbas Kazimi's leadership at Nimbus Therapeutics combines immigrant resilience, patient-first partnerships, contrarian strategic bets and a deeply personal mission driving breakthrough drug discovery innovation.

Podcast: Oxolife’s Agnés Arbat, Winner Of The European Prize For Women Innovators

14 Jul 2025

• By Jo Shorthouse

Agnès Arbat, CEO of Oxolife and winner of the EU Women Innovators Prize, joins In Vivo to discuss OXO-001, a novel non-hormonal treatment aimed at improving embryo implantation in IVF. She shares insights from her biotech journey and the future of fertility innovation.